Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
6.80
-0.29 (-4.09%)
At close: Apr 28, 2026, 4:00 PM EDT
6.85
+0.05 (0.74%)
After-hours: Apr 28, 2026, 6:05 PM EDT
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cartesian Therapeutics stock have an average target of 34, with a low estimate of 16 and a high estimate of 44. The average target predicts an increase of 400.00% from the current stock price of 6.80.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 10, 2026.
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $38 | Buy | Reiterates | $38 | +458.82% | Mar 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades $16 | Hold → Buy | Upgrades | $16 | +135.29% | Mar 9, 2026 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +517.65% | Mar 9, 2026 |
| Needham | Needham | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +517.65% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +341.18% | Nov 19, 2025 |
Financial Forecast
Revenue This Year
407.49K
from 2.80M
Decreased by -85.43%
Revenue Next Year
407.49K
from 407.49K
EPS This Year
-3.32
from -5.02
EPS Next Year
-3.49
from -3.32
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.5M | 2.5M | ||||||
| Avg | 407,490 | 407,490 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -10.0% | 517.7% | ||||||
| Avg | -85.4% | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.64 | -2.06 | |||
| Avg | -3.32 | -3.49 | |||
| Low | -3.87 | -4.31 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.